Hot Products

Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.

Hot products from the professional high-purity natural products manufacturer

Cat.No. Product Name
BCC6590 (1S,3R)-ACPD
Active isomer of (±)-trans-ACPD. Agonist at both group I and II mGlu receptors (EC50 values are 5, 15, 42 and 60 μM at mGluR2, mGluR5, mGluR1 and mGluR6 respectively). NPEC-caged-(1S,3R)-ACPD also available . (±)-trans-ACPD and cis-ACPD also available.
BCC6593 Muscimol
Potent GABAA receptor agonist and partial GABAA-ρ receptor agonist. Inhibits memory retention and attenuates airway constriction in vivo.
BCC6614 nor-Binaltorphimine dihydrochloride
A selective κ-opioid receptor antagonist.
BCC6616 4-Acetyl-1,1-dimethylpiperazinium iodide
Structural analog of acetylcholine that acts as a nicotinic agonist (Ki = 29.9 nM at α4β2). Upregulates the number of α4β2 binding sites in M10 cells in vitro by 440%.
BCC6620 W-13 hydrochloride
Calmodulin antagonist (inhibits calmodulin activated PDE activity with an IC50 of 68 μM). Inhibits growth of tamoxifen-resistant breast cancer cells.
BCC6621 W-5 hydrochloride
Calmodulin antagonist (inhibits Ca2+-calmodulin dependent PDE with an IC50 of 240 μM).
BCC6622 W-7 hydrochloride
Calmodulin antagonist. Inhibits Ca2+-calmodulin-dependent phosphodiesterase (IC50 = 28 μM) and myosin light chain kinase (IC50 = 51 μM).
BCC6623 W-9 hydrochloride
Calmodulin antagonist (inhibits calmodulin-activated PDE activity with an IC50 of 72 μM).